Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8351 to 8400 of 8899 results

  1. Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy (TA295)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA421.

    Withdrawn guidance

  2. Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene (TA296)

    This guideance has been updated and replaced by NICE technology appraisal guidance 422.

    Withdrawn guidance

  3. Ocriplasmin for treating vitreomacular traction (TA297)

    We have withdrawn this guidance. Inceptua has stopped marketing Ocriplasmin (Jetrea) and its marketing authorisation has been withdrawn.

    Withdrawn guidance

  4. Bosutinib for previously treated chronic myeloid leukaemia (TA299)

    This guidance has been updated and replaced by NICE technology appraisal guidance 401. 

    Withdrawn guidance

  5. The clinical effectiveness and cost effectiveness of irinotecan, oxaliplatin and raltitrexed for colorectal cancer (TA33)

    This guidance has been replaced by NICE technology appraisal guidance 93 [Replaced by NICE guideline CG131].

    Withdrawn guidance

  6. Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (TA331)

    The guidance has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.

    Withdrawn guidance

  7. Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer (TA332)

    This appraisal has been withdrawn. This is because the marketing authorisation for sipuleucel-T was withdrawn on 19 May 2015.

    Withdrawn guidance

  8. Ovarian cancer - taxanes (TA3)

    This guidance has been replaced by NICE technology appraisal guidance 55. 

    Withdrawn guidance

  9. Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal) (TA281)

    This guidance has been updated and replaced by NICE guideline NG219.

    Withdrawn guidance

  10. Pirfenidone for treating idiopathic pulmonary fibrosis (TA282)

    This guidance has been updated and replaced by NICE technology appraisal guidance 504.

    Withdrawn guidance

  11. Ovarian cancer - topotecan (TA28)

    This guidance has been replaced by NICE technology appraisal guidance 91.

    Withdrawn guidance

  12. Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (TA280)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Withdrawn guidance

  13. Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]

    Discontinued Reference number: GID-TA11712

    Technology appraisal guidance
    Discontinued

  14. Baloxavir marboxil for treating and preventing influenza in people 3 weeks to 11 years [ID6554]

    In development Reference number: GID-TA11732 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Intramedullary distraction for lower limb lengthening (IPG197)

    This guidance has been updated and replaced by NICE HealthTech guidance 613.

    Withdrawn guidance

  16. Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA10)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  17. Parent-training/education programmes in the management of children with conduct disorders (TA102)

    This guidance has been updated and replaced by NICE guideline CG158.

    Withdrawn guidance

  18. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA349)

    This guidance has been updated and replaced by NICE technology appraisal guidance 824.

    Withdrawn guidance

  19. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis (TA35)

    This guidance has been updated and replaced by NICE technology appraisal guidance 373.

    Withdrawn guidance

  20. Inhaler devices for routine treatment of chronic asthma in older children (aged 5 to 15 years) (TA38)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  21. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)

    This guidance has been updated and replaced by NICE technology appraisal guidance 908.

    Withdrawn guidance

  22. Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (TA344)

    This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

    Withdrawn guidance

  23. Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA921.

    Withdrawn guidance

  24. The clinical effectiveness and cost effectiveness of etanercept and infliximab for rheumatoid arthritis and juvenile poly-articular idiopathic arthritis (TA36)

    This guidance has been replaced by NICE technology appraisal guidance 130 and NICE technology appraisal guidance 195.

    Withdrawn guidance

  25. Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (TA360)

    This guidance has been updated and replaced by NICE technology appraisal guidance 476.

    Withdrawn guidance

  26. Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) (TA361)

    The appraisal has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.

    Withdrawn guidance

  27. Daclatasvir for treating chronic hepatitis C (TA364)

    This guidance has been withdrawn because Bristol-Myers Squibb has discontinued daclatasvir (Daklinza).

    Withdrawn guidance

  28. Apremilast for treating moderate to severe plaque psoriasis (TA368)

    Withdrawn guidance

  29. The clinical effectiveness and cost effectiveness of rituximab for follicular lymphoma (TA37)

    This guidance has been updated and replaced by NICE technology appraisal guidance 137.

    Withdrawn guidance

  30. Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane (TA371)

    This guidance has been updated and replaced by NICE technology appraisal guidance 458.

    Withdrawn guidance

  31. Apremilast for treating active psoriatic arthritis (TA372)

    This guidance has been updated and replaced by NICE technology appraisal guidance 433.

    Withdrawn guidance

  32. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA376)

    This guidance has been updated and replaced by NICE technology appraisal guidance 412.

    Withdrawn guidance

  33. The clinical effectiveness and cost effectiveness of bupropion (Zyban) and Nicotine Replacement Therapy for smoking cessation (TA39)

    This guidance has been updated and replaced by NICE guideline PH10. 

    Withdrawn guidance

  34. Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (TA338)

    This guidance has been updated and replaced by NICE technology appraisal guidance 427.

    Withdrawn guidance

  35. Hearing disability - hearing aids (TA8)

    This guidance has been withdrawn.

    Withdrawn guidance

  36. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)

    This guidance has been replaced by recommendations 1.3.4 to 1.3.8 in NICE guideline CG94 and by recommendation 1.3.18 in NICE guideline CG172.

    Withdrawn guidance

  37. Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1038.

    Withdrawn guidance

  38. Crizanlizumab for preventing sickle cell crises in sickle cell disease (TA743)

    NICE has withdrawn this guidance. Novartis will stop marketing crizanlizumab (Adakveo) because its marketing authorisation has been withdrawn by the Medicines and Healthcare products Regulatory Agency (MHRA). Novartis has issued a direct letter to healthcare professionals specialising in haematology. No new people will start taking crizanlizumab in the UK. Healthcare professionals should discuss alternative treatment options with people currently having crizanlizumab.

    Withdrawn guidance

  39. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1018.

    Withdrawn guidance

  40. Fostamatinib for treating refractory chronic immune thrombocytopenia (TA759)

    This guidance has been updated and replaced by NICE technology appraisal guidance 835.

    Withdrawn guidance

  41. Newer drugs for epilepsy in adults (TA76)

    This guideline has been updated and replaced by NICE guideline CG137.

    Withdrawn guidance

  42. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA1042

    Withdrawn guidance

  43. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA761)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1043.

    Withdrawn guidance

  44. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) (TA762)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1040.

    Withdrawn guidance

  45. Dapagliflozin for treating chronic kidney disease (TA775)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1075.

    Withdrawn guidance

  46. The clinical effectiveness and cost effectiveness of anakinra for rheumatoid arthritis (TA72)

    This appraisal has been updated and replaced by NICE guideline CG79. 

    Withdrawn guidance

  47. Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1110.

    Withdrawn guidance

  48. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA831)

    This guidance has been updated and replaced by NICE technology appraisal guidance 887.

    Withdrawn guidance

  49. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1071.

    Withdrawn guidance

  50. Newer drugs for epilepsy in children (TA79)

    This guideline has been updated and replaced by NICE guideline CG137.

    Withdrawn guidance